Kite Pharma

October 19, 2017

FDA Approves Yescarta, First CAR T-cell Therapy for Lymphoma

News

The U.S. Food and Drug Administration (FDA) approved Kite Pharma‘s Yescarta (axicabtagene ciloleucel) for the treatment of relapsed or refractory large B-cell lymphoma patients who received at least two prior ... Read more

August 29, 2017August 29, 2017

Gilead to Become Cell Therapy Leader Once $11.9B Acquisition of Kite Pharma Closes

News

Just a few months before the U.S. Food and Drug Administration is expected to reach a decision on Kite Pharma‘s application seeking approval for its therapy axicabtagene ciloleucel (axi-cel) for the treatment ... Read more

August 7, 2017August 7, 2017

B-Cell Non-Hodgkin Lymphoma Patients Begin Treatment with Axicabtagene Ciloleucel in Phase 2 Trial

News

Patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (iNHL) have begun treatment with axicabtagene ciloleucel (axi-cel) in the Phase 2 ZUMA-5 trial, the immunotherapy’s developer, Kite Pharma, announced. The trial (NCT03105336) is currently recruiting participants ... Read more

August 3, 2017

Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes

News

Kite Pharma submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) requesting the approval of its CAR T-cell therapy, axicabtagene ciloleucel, as treatment for patients with certain ... Read more

July 12, 2017July 12, 2017

Lymphoma Therapy Developer Kite Is Number 7 on MIT Technology Review’s List of 50 Smartest Companies

News

Kite Pharma is ranked #7 on MIT Technology Review’s list of the 50 Smartest Companies for its pioneering work in engineered cell therapy for treating cancer. The company received the recognition for ... Read more

July 7, 2017July 7, 2017

Response to Kite’s CAR T-Cell Therapy in NHL Isn’t Dependent on Disease Factors, Researchers Say

News

The ZUMA-1 Phase 2 clinical trial of the CAR T-cell therapy axicabtagene ciloleucel (KTE-C19) showed that 82% of patients with treatment-resistant or relapsed aggressive non-Hodgkin’s lymphoma (NHL) responded to the ... Read more

May 30, 2017

FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application (BLA) seeking the approval of axicabtagene ciloleucel (KTE-C19) for the treatment of refractory aggressive non-Hodgkin’s ... Read more

April 6, 2017

Kite Presents Positive Data from ZUMA-1 Trial in Aggressive Non-Hodgkin’s Lymphoma Patients

News

ZUMA-1, Kite Pharma‘s Phase 1/2 trial assessing the CAR T-cell therapy axicabtagene ciloleucel in patients with aggressive B-cell non-Hodgkin’s lymphoma has reached its primary endpoint of objective response rate, according ... Read more

March 17, 2017March 17, 2017

Kite’s CAR T-cell Therapy Helps Aggressive Lymphoma Patients, Clinical Trial Shows

News

Eighty-two percent of patients with refractory aggressive lymphoma have responded to Kite Pharma‘s KTE-C19 chimeric antigen receptor (CAR) T-cell therapy, and 36 percent have achieved complete remission, according to preliminary results of a clinical ... Read more

March 2, 2017

Kite’s CAR T-cell Therapy Could Markedly Benefit NHL Patients, ZUMA-1 Data Suggests

News

Kite Pharma‘s lead CAR T-cell therapy axicabtagene ciloleucel may be a promising therapeutic approach for patients with refractory, aggressive non-Hodgkin lymphoma (NHL), according to primary data from the ZUMA-1 Phase 1/2 ... Read more